Company Overview
Company Type: Private Company
Website: searchlightpharma.com
Number of Employees: -
Year Founded: 2014
Total Amount Raised (CAD mm)†: 6.85
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Searchlight Pharma Inc. is a specialty pharmaceutical company that engages in the search, acquisition, commercialization, and focused development of specialty healthcare products that improve human health and wellness. The company focuses on women’s health, urology, sports medicine, and pediatrics. It develops a pipeline of specialty prescription, over-the-counter, and device products, such as Estragyn Vaginal Cream, a prescription medication indicated for the treatment of the symptoms of vulvovaginal atrophy due to estrogen deficiency; Oesclim Transdermal System, a prescription formulation of estradiol-17B indicated for the relief of menopausal and post-menopausal symptoms; Hyalfem Gel, an intimate feminine vaginal moisturizer to relieve the symptoms and discomfort of vaginal dryness; Cysta-Q, a non-prescription quercetin-based phytotherapeutic compound indicated for the relief of symptoms of painful bladder syndrome; Q-Urol, a non-prescription quercetin-based phytotherapeutic compound indicated for the relief of symptoms of chronic pelvic pain syndrome; and Dipentum, a prescription medication indicated for the long-term maintenance of patients with ulcerative colitis in remission and the treatment of acute ulcerative colitis of mild to moderate severity. The company was incorporated in 2014 and is headquartered in Montreal, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Nawacki, Mark H.
Chief Executive Officer and President
Kushneryk, Geri-Lynn 
Chief Financial Officer
Vinson, Robert 
Chief Innovation Officer


Primary Industry Classification
Pharmaceuticals


Primary Office Location
1600 Notre-Dame Street West Suite 312 | Montreal, QC | H3J 1M1 | Canada
Phone: 514-613-1513   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
CIC Capital Ventures
Oct-25-2017
Minority
-
Venture
Crédit Mutuel Equity
Oct-25-2017
Minority
-
Venture
Fonds de solidarité FTQ
Oct-25-2017
Minority
-
Venture
CIC Capital (Schweiz) AG
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada. As of March 14, 2023, Nuvo Pharmaceuticals Inc. operates as a subsidiary of Searchlight Pharma Inc.

United States and Canada
Pharmaceuticals
53.00
94.00
73.00
ERFA Canada 2012 Inc.
ERFA Canada 2012 Inc. provides pharmaceuticals, natural health products, and medical devices. It offers products in the areas of cardiovascular/respiratory, central nervous system, endocrinology/metabolic, oncology, and antibiotic/antiseptic. The company was formerly known as Industrie Acquiserfa Inc. ERFA Canada 2012 Inc. was founded in 1998 and is based in Montréal, Canada. As of January 5, 2022, ERFA Canada 2012 Inc. operates as a subsidiary of Searchlight Pharma Inc.

United States and Canada
Pharmaceuticals
28.00
-
-
Besins Healthcare Canada Inc.
Besins Healthcare Canada Inc., a pharmaceutical company, specializes in healthcare solutions that restore, restart, and regulate female and male body processes. The company offers Femarelle, a twice-daily supplement to relieve menopausal symptoms and support bone health; and Relactagel, a pH regulator vaginal gel to relieve and prevent symptoms of bacterial vaginosis. It sells its products through local pharmacies and wholesalers. The company is based in Kirkland, Canada. As of June 9, 2016, Besins Healthcare Canada Inc. operates as a subsidiary of Searchlight Pharma Inc.

United States and Canada
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Mar-27-2023
Mar-27-2023
Private Placement
Target
Searchlight Pharma Inc.
Fonds de solidarité FTQ

5.00
Dec-23-2022
Mar-14-2023
Merger/Acquisition
Buyer
Nuvo Pharmaceuticals Inc.
Searchlight Pharma Inc.
Red Oak Partners, LLC
84.28
Jan-05-2022
Jan-05-2022
Merger/Acquisition
Buyer
ERFA Canada 2012 Inc.
Searchlight Pharma Inc.

-
Oct-25-2017
Oct-25-2017
Private Placement
Target
Searchlight Pharma Inc.
CIC Capital Ventures,Fonds de solidarité FTQ,CM-CIC Capital Finance (nka:Crédit Mutuel Equity)

-
Jun-09-2016
Jun-09-2016
Merger/Acquisition
Buyer
Besins Healthcare Canada Inc.
Searchlight Pharma Inc.
Besins Healthcare Sa
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-31-2023
Client Announcements
Mithra and Searchlight Pharma Announces Donesta® Licensing Agreement for Canada
Apr-25-2023
Company Conference Presentations
Searchlight Pharma Inc. Presents at 2023 Bloom Burton & Co. Healthcare Investor Conference, Apr-25-2023 03:00 PM
Mar-27-2023
Private Placements
Searchlight Pharma Inc. announced that it has received $5 million in funding from Fonds de solidarité FTQ
Mar-14-2023
M&A Transaction Closings
Searchlight Pharma Inc. completed the acquisition of Nuvo Pharmaceuticals Inc. (TSX:MRV) from Red Oak Partners, LLC and other shareholders.
Dec-23-2022
M&A Transaction Announcements
Searchlight Pharma Inc. entered into a definitive agreement to acquire Nuvo Pharmaceuticals Inc. (TSX:MRV) from Red Oak Partners, LLC and other shareholders for CAD 15.4 million.

Competitors
Bausch Health Companies Inc. (NYSE:BHC), HLS Therapeutics Inc. (TSX:HLS), Knight Therapeutics Inc. (TSX:GUD), Valeo Pharma Inc. (TSX:VPH)

M&A Advisors
Bloom Burton Securities Inc., Davies Ward Phillips & Vineberg LLP, Ernst & Young LLP, McCarthy Tétrault LLP, PricewaterhouseCoopers Corporate Finance Inc., PricewaterhouseCoopers LLP, Canada


Advisors
M&A Advisors
Bloom Burton Securities Inc., Davies Ward Phillips & Vineberg LLP, Ernst & Young LLP, McCarthy Tétrault LLP, PricewaterhouseCoopers Corporate Finance Inc., PricewaterhouseCoopers LLP, Canada


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 09:14 PM
Searchlight Pharma Inc.
Searchlight Pharma Inc
Reports
37
GlobalData

Jul 27, 2023 07:01 AM
Searchlight Pharma Inc.
Searchlight Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
25
GlobalData

Jun 28, 2023 04:12 AM
Searchlight Pharma Inc.
Searchlight Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
25
GlobalData

Jun 15, 2023 11:27 PM
Searchlight Pharma Inc.
Searchlight Pharma Inc
Reports
36
GlobalData

Mar 15, 2023 03:08 AM
Searchlight Pharma Inc.
Searchlight Pharma Inc
Reports
36
GlobalData

Feb 20, 2023 05:42 AM
Searchlight Pharma Inc.
Searchlight Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Dec 14, 2022 05:35 PM
Searchlight Pharma Inc.
Searchlight Pharma Inc
Reports
34
GlobalData

Sep 19, 2022 08:43 AM
Searchlight Pharma Inc.
Searchlight Pharma Inc
Reports
34
GlobalData

Jun 16, 2022 01:41 AM
Searchlight Pharma Inc.
Searchlight Pharma Inc
Reports
34
GlobalData

Jun 15, 2022 02:33 AM
Searchlight Pharma Inc.
Searchlight Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
21


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Nawacki, Mark H.
Chief Executive Officer and President
514-613-1513
-

Kushneryk, Geri-Lynn 
Chief Financial Officer
514-613-1513
-

Vinson, Robert 
Chief Innovation Officer
514-613-1513
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
